The Innovation Institute, for-profit company comprised of six owner health systems:
• Sioux Falls, S.D.-based Avera Health
• Marriottsville, Md.-based Bon Secours Health System
• Orange, Calif.-based CHOC Children’s
• Baton Rouge, La.-based Franciscan Missionaries of Our Lady Health System
• Cincinnati-based Mercy Health
• Renton, Wash.-based Providence St. Joseph Health
Per the agreement, all the health systems will have access to Avera Health’s GeneFolio, a gene test that uses a saliva or blood sample. The systems will then be able to use 2bPrecise’s precision medicine platform to harmonize the results achieved by GeneFolio and convert it into an actionable format for clinicians.
Avera Health launched GeneFolio in 2017. It tests multiple genes that impact medications in the following areas: pain, depression and other psychiatric disorders as well as statins for cholesterol and certain types of blood thinners.
The 2bPrecise platform is cloud-based, scalable and EHR-agnostic allowing clinicians to access genomic insights provided by GeneFolio within the existing workflows.
More articles on precision medicine:
ONC names 2 winners of health data challenge
4 legal questions on sharing EHR data with public health agencies, answered
Aurora Health Care, U of Texas Health Sciences join Strata Precision Oncology Network
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
